Skip to content
HowShorted

BIOCRYST PHARMACEUTICALS INC short interest in 2020

In 2020, BIOCRYST PHARMACEUTICALS INC's disclosed short interest ran from 14.61% of shares outstanding on 15 Jan 2020 to 17.53% on 31 Dec 2020, a change of +2.92 percentage points. The year's high was 23.40% on 30 Oct 2020 and its low 9.69% on 28 Feb 2020, averaging 16.33% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.12 days on 30 Oct 2020. Full history: BIOCRYST PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for BIOCRYST PHARMACEUTICALS INC in 2020

2020 in figures

Start of year
14.61% (15 Jan 2020)
End of year
17.53% (31 Dec 2020)
Change
+2.92 pp
High
23.40% (30 Oct 2020)
Low
9.69% (28 Feb 2020)
Average
16.33%
Highest days to cover
10.12 (30 Oct 2020)
SEC filings marked
8

Every report in 2020

BIOCRYST PHARMACEUTICALS INC short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202014.61%7.53
31 Jan 202010.41%3.05
14 Feb 20209.92%6.45
28 Feb 20209.69%2.78
13 Mar 202010.41%1.56results (8-K), 10-K filed
31 Mar 202010.29%2.74
15 Apr 202011.43%2.06
30 Apr 202011.60%1.19
15 May 202011.07%1.24results (8-K), 10-Q filed
29 May 202011.95%2.08
15 Jun 202013.38%3.65
30 Jun 202020.81%3.81
15 Jul 202020.16%4.17
31 Jul 202019.26%6.15
14 Aug 202021.53%5.64results (8-K), 10-Q filed
31 Aug 202019.00%8.79
15 Sep 202019.62%6.63
30 Sep 202020.61%8.00
15 Oct 202021.58%9.88
30 Oct 202023.40%10.12
13 Nov 202021.56%8.76results (8-K), 10-Q filed
30 Nov 202021.19%9.15
15 Dec 202020.98%2.85
31 Dec 202017.53%4.24

See also: BIOCRYST PHARMACEUTICALS INC's full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.